These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 2146577)

  • 1. [Long-term results of the anti-emetic effectiveness of the 5-HT3 antagonist ondansetron].
    Marschner NW; Adler M; Jaenicke F; Albrecht U; Nagel GA
    Onkologie; 1990 Aug; 13(4):313-5. PubMed ID: 2146577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
    Bonneterre J; Chevallier B; Metz R; Fargeot P; Pujade-Lauraine E; Spielmann M; Tubiana-Hulin M; Paes D; Bons J
    J Clin Oncol; 1990 Jun; 8(6):1063-9. PubMed ID: 2140854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Ondansetron (GR 38032F), a competitive 5-HT3 receptor antagonist as an antiemetic in cytostatic drug-induced nausea and vomiting. An open, substance-oriented phase II/III study].
    Serve H; Perker M; Ertl A; Reichold M; Fink U; Berdel WE
    Onkologie; 1990 Oct; 13(5):369-74. PubMed ID: 2150552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-emetic control with ondansetron in the chemotherapy of breast cancer: a review.
    Marschner N
    Eur J Cancer; 1991; 27 Suppl 1():S15-7; discussion S22. PubMed ID: 1831629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide.
    Marschner NW; Adler M; Nagel GA; Christmann D; Fenzl E; Upadhyaya B
    Eur J Cancer; 1991; 27(9):1137-40. PubMed ID: 1835624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. International Emesis Study Group.
    Kaasa S; Kvaløy S; Dicato MA; Ries F; Huys JV; Royer E; Carruthers L
    Eur J Cancer; 1990 Mar; 26(3):311-4. PubMed ID: 2141487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy.
    Fraschini G; Ciociola A; Esparza L; Templeton D; Holmes FA; Walters RS; Hortobagyi GN
    J Clin Oncol; 1991 Jul; 9(7):1268-74. PubMed ID: 1828499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor-antagonist in moderately emetogenic chemotherapy.
    Massidda B; Ionta MT
    J Chemother; 1996 Jun; 8(3):237-42. PubMed ID: 8808724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens.
    Cubeddu LX; Hoffman IS; Fuenmayor NT; Finn AL
    J Clin Oncol; 1990 Oct; 8(10):1721-7. PubMed ID: 2145400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiemetic control: 5-HT3 antagonists: review of clinical results, with particular emphasis on ondansetron.
    Kidgell AE; Butcher ME; Brown GW
    Cancer Treat Rev; 1990 Sep; 17(2-3):311-7. PubMed ID: 2176933
    [No Abstract]   [Full Text] [Related]  

  • 12. High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer.
    Bosnjak SM; Nesković-Konstantinović ZB; Radulović SS; Susnjar S; Mitrovi LB
    J Chemother; 2000 Oct; 12(5):446-53. PubMed ID: 11128567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of ondansetron in the treatment of emesis induced by non-cisplatin-containing chemotherapy regimes.
    Schmoll HJ
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S35-9. PubMed ID: 2533897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral ondansetron (GR38032F) for the control of acute and delayed cyclophosphamide-induced emesis.
    Rosso R; Campora E; Cetto G; Fosser V; Marangolo M; Oliva C
    Anticancer Res; 1991; 11(2):937-9. PubMed ID: 1829602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Italian Group For Antiemetic Research.
    Lancet; 1992 Jul; 340(8811):96-9. PubMed ID: 1352024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of cyclophosphamide/cytarabine-induced emesis with ondansetron in children with leukemia.
    Carden PA; Mitchell SL; Waters KD; Tiedemann K; Ekert H
    J Clin Oncol; 1990 Sep; 8(9):1531-5. PubMed ID: 2144019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiemetic activity of ondansetron in cancer patients receiving non-cisplatin chemotherapy.
    Fraschini G
    Semin Oncol; 1992 Aug; 19(4 Suppl 10):41-7. PubMed ID: 1387249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting.
    Bosnjak SM; Neskovic-Konstantinovic ZB; Jovanovic-Micic DJ; Mitrovic LB; Radulovic SS
    J Chemother; 1996 Aug; 8(4):315-8. PubMed ID: 8873840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiemetic prophylaxis with ondansetron and methylprednisolone vs metoclopramide and methylprednisolone in mild and moderately emetogenic chemotherapy.
    Tsavaris NB; Koufos C; Katsikas M; Dimitrakopoulos A; Athanasiou E; Linardaki G
    J Pain Symptom Manage; 1999 Sep; 18(3):218-22. PubMed ID: 10517044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of an orally disintegrating ondansetron tablet with the conventional ondansetron tablet for cyclophosphamide-induced emesis in cancer patients: a multicenter, double-masked study. Ondansetron Orally Disintegrating Tablet Emesis Study Group.
    Davidson N; Rapoport B; Erikstein B; L'Esperance B; Ruff P; Paska W; Miller I; Curtis P
    Clin Ther; 1999 Mar; 21(3):492-502. PubMed ID: 10321418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.